Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas - 24 Oct 2016

Zanaga L P, Miotto N, Mendes L C, Stucchi R S B, Vigani A G

Abstract excerpt

Hepatitis C virus (HCV) genotype 3 is responsible for 30.1% of chronic hepatitis C infection cases worldwide. In the era of direct-acting antivirals, these patients have become one of the most challenging to treat, due to fewer effective drug options, higher risk of developing cirrhosis and hepatocellular carcinoma and lower sustained virological response (SVR) rates. Currently there are 4 recommended drugs for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Liver Cirrhosis

Share to Pyrrolidines

Share to Ribavirin

Share to Sofosbuvir

Share to Valine

Source

Open in PubMed Open full text

Identifiers

PMID: 27783808
DOI: 10.1590/1414-431X20165504
PMCID: PMC5089232

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents.PMID 27783808Read ↗

Therapy for hepatitis C genotype 3: moving forward.Semantic proximity Read ↗

Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.Semantic proximity Read ↗

Treatment of hepatitis C in patients with cirrhosis: remaining challenges for direct-acting antiviral therapy.Semantic proximity Read ↗

Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.Semantic proximity Read ↗

Update on the treatment of hepatitis C genotypes 2-6.Semantic proximity Read ↗

Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection.Semantic proximity Read ↗

Interferon-free treatments in patients with hepatitis C genotype 3 infection in a tertiary hospital.Semantic proximity Read ↗

Treatment of hepatitis C: a systematic review.Semantic proximity Read ↗

Current therapy for chronic hepatitis C: The role of direct-acting antivirals.Semantic proximity Read ↗

Review of direct-acting antiviral agents for the treatment of chronic hepatitis C.Semantic proximity Read ↗

Direct-acting antiviral agents in patients with hepatitis C genotype 1-4 infections in a tertiary hospital.Semantic proximity Read ↗

Treatment of hepatitis C virus genotype 3-infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.